Rice University researchers, led by Professor Michael King and doctoral student Alexandria Carter, have developed the Advanced Tumor Landscape Analysis System (ATLAS) to model meta...

Rice University researchers, led by Professor Michael King and doctoral student Alexandria Carter, have developed the Advanced Tumor Landscape Analysis System (ATLAS) to model metastatic cancer cell clusters. The platform utilizes 3D printed microwell arrays treated to achieve superhydrophobic, nanoscale surface roughness, replicating the conditions cancer cells encounter in the bloodstream. This method enables the generation of large quantities of 3D cell clusters, including prostate cancer cells and cancer-associated fibroblasts, at a lower cost and higher efficiency than existing laboratory techniques. The research, published in Advanced Healthcare Materials, is currently transitioning toward commercialization through the startup Bionostic.

This development addresses a critical bottleneck in oncology research by providing a scalable, reproducible method for studying metastasis, which remains poorly understood due to the lack of adequate in vitro models. While traditional microfluidic or cell culture methods often struggle with cost and throughput, the use of 3D printed, superhydrophobic surfaces offers a more accessible pathway for academic and clinical labs to standardize tumor microenvironment simulations. The ability to mass-produce these clusters allows for more robust testing of potential drug targets, specifically those focusing on the protective role of fibroblasts in cancer cell survival. This application highlights the growing utility of precision 3D printing in life sciences, moving beyond simple anatomical models into functional, bio-mimetic research tools.

For researchers and biotech firms, the adoption of ATLAS represents a shift toward standardized, high-throughput biological testing platforms that leverage additive manufacturing for surface engineering. The scalability of this 3D printing approach suggests that labs can now produce complex, non-wetting surfaces in-house rather than relying on expensive, proprietary micro-molding processes. Future efforts should focus on validating the platform across a broader range of cancer cell lines to confirm the universality of the observed fibroblast-assisted survival mechanisms. Commercial success for Bionostic will depend on the ease of integration into existing high-throughput screening workflows used by pharmaceutical companies.